Last updated on November 2018

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis


Brief description of study

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Clinical Study Identifier: NCT02092467

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Lekarna Halasovo namesti
Brno, Czechia
7.33miles
  Connect »

Pfizer CT.gov Call Center

Revmatologie, s.r.o.
Brno, Czechia
7.33miles
  Connect »

Pfizer CT.gov Call Center

DC- FLIPPER s.r.o.
Brno, Czechia
7.42miles
  Connect »

Pfizer CT.gov Call Center

X-MEDICA s.r.o., radiodiagnostika
Brno, Czechia
8.49miles
  Connect »

Pfizer CT.gov Call Center

Revmacentrum MUDr. Mostera, s.r.o.
Brno - Zidenice, Czechia
8.85miles
  Connect »

Pfizer CT.gov Call Center

Lekarna Na Lidicke
Brno, Cerna Pole, Czechia
9.44miles
  Connect »

Pfizer CT.gov Call Center

REVMACLINIC s.r.o.
Brno, Czechia
9.83miles
  Connect »

Pfizer CT.gov Call Center

Revmaclinic, S.r.o.
Brno, Czechia
9.83miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.